An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
Ann & Robert H Lurie Children's Hospital of Chicago
Summary
The primary objective of this study is to evaluate a potential behavioral intervention (MED-Go app). To meet this objective, the researchers will conduct a pilot randomized controlled trial to test the feasibility and acceptability of MED-Go app in adolescents and young adults (AYA) with sickle cell disease (SCD). The long-term goal of this research is to promote medication adherence behavior and improve health outcomes in AYA with SCD.
Description
Sickle cell disease is the most common genetic disorder in the US, affecting about 100,000 Americans, and about 1 in 400 African American live births, incurring annual health care costs of $335 million. SCD can lead to serious complications including unpredictable, debilitating pain episodes, cardiopulmonary disease, stroke, and long-term end organ damage.These complications lead to significant declines in health-related quality of life (HRQOL) and other patient-reported outcomes (PROs), culminating in early mortality, particularly among AYA. Hydroxyurea (HU), at present, is the main FDA appro…
Eligibility
- Age range
- 12–21 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age 12-21 years old * Any sickle cell disease genotype * On steady state of hydroxyurea for 2 months * Own of have access to a smartphone during the study period Exclusion Criteria: * Recent hospitalizations within the past 7 days
Interventions
- BehavioralMED-Go App
A novel multifunctional mobile app (MED-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
Location
- Ann & Robert H Lurie Children's Hospital of ChicagoChicago, Illinois